Table 2.
Serum concentrations of C-reactive Protein by tumor characteristics in breast cancer survivors of the Women's Healthy Eating and Living Study
| Distribution of Inflammatory Status | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No Inflammation |
Low Inflammation |
Moderate Inflammation |
Acute Inflammation |
||||||||
| Serum CRP mg/L | <1 mg/L | 1–3 mg/L | >3 to <10 mg/L | ≥10 mg/L | |||||||
| n (%) | Geometric mean | No. | % | No. | % | No. | % | No. | % | P | |
| Tumor Stage | 0.007 | ||||||||||
| I | 1144 (39.2) | 1.54 (0.58, 3.91) | 418 | 42.6 | 360 | 38.6 | 277 | 36.9 | 89 | 34.9 | |
| II | 1333 (45.7) | 1.73 (0.71, 4.17) | 527 | 53.7 | 538 | 57.7 | 424 | 56.5 | 150 | 58.8 | |
| IIIA | 442 (15.1) | 2.2 (0.94, 5.55) | 36 | 3.7 | 35 | 3.8 | 49 | 6.5 | 16 | 6.3 | |
| Tumor Grade | 0.097 | ||||||||||
| 1 - Well differentiated | 463 (15.9) | 1.51 (0.54, 4.23) | 181 | 18.5 | 131 | 14.0 | 109 | 14.5 | 42 | 16.5 | |
| 2 - Moderately differentiated | 1184 (40.6) | 1.64 (0.66, 3.88) | 397 | 40.5 | 395 | 42.3 | 302 | 40.3 | 90 | 35.3 | |
| 3 - Poorly differentiated | 1027 (35.2) | 1.92 (0.77, 4.87) | 316 | 32.2 | 331 | 35.5 | 278 | 37.1 | 102 | 40.0 | |
| Unspecified | 245 (8.4) | 1.66 (0.63, 4.04) | 87 | 8.9 | 76 | 8.1 | 61 | 8.1 | 21 | 8.2 | |
| Estrogen/Progesterone Receptor Status | 0.003 | ||||||||||
| ER+/PR+ | 1818 (62.3) | 1.60 (0.64, 4.02) | 631 | 64.3 | 597 | 64.0 | 459 | 61.2 | 135 | 52.9 | |
| ER+/PR− | 331 (11.3) | 1.53 (0.63, 3.83) | 121 | 12.3 | 106 | 11.4 | 84 | 11.2 | 22 | 8.6 | |
| ER−/PR+ | 121 (4.2) | 1.73 (0.57, 4.35) | 42 | 4.3 | 33 | 3.5 | 34 | 4.5 | 12 | 4.7 | |
| ER−/PR− | 582 (19.9) | 2.20 (0.85, 5.50) | 170 | 17.3 | 179 | 19.2 | 154 | 20.5 | 78 | 30.6 | |
| Unknown | 67 (2.3) | 2.20 (0.91, 6.06) | 17 | 1.7 | 18 | 1.9 | 19 | 2.5 | 8 | 3.1 | |
| Her2 Receptor Status | 0.605 | ||||||||||
| Positive | 360 (12.3) | 1.72 (0.66, 4.22) | 123 | 12.5 | 108 | 11.6 | 100 | 13.3 | 29 | 11.4 | |
| Negative | 1672 (57.3) | 1.74 (0.70,4.26) | 542 | 55.2 | 543 | 58.2 | 438 | 58.4 | 149 | 58.4 | |
| Unknown | 887 (30.4) | 1.66 (0.65, 4.17) | 316 | 32.2 | 282 | 30.2 | 212 | 28.3 | 77 | 30.2 | |
| Treatment (after surgery) | 0.597 | ||||||||||
| No chemotherapy or radiation | 321 (11.0) | 1.56 (0.58, 3.86) | 112 | 11.4 | 106 | 11.4 | 74 | 9.9 | 29 | 11.4 | |
| Radiation only | 569 (19.5) | 1.63 (0.66, 4.00) | 196 | 20.0 | 193 | 20.7 | 140 | 18.7 | 40 | 15.7 | |
| Chemotherapy only | 794 (27.2) | 1.76 (0.66, 4.17) | 255 | 26.0 | 258 | 27.7 | 205 | 27.3 | 76 | 29.8 | |
| Radiation and chemotherapy | 1230 (42.1) | 1.76 (0.71, 4.56) | 415 | 42.3 | 375 | 40.2 | 331 | 44.1 | 109 | 42.7 | |
| Unknown | 5 (0.17) | 0.85 (0.25,2.68) | 3 | 0.3 | 1 | 0.1 | 0 | 0.0 | 1 | 0.4 | |
| Current Anti-estrogen use | <0.001 | ||||||||||
| Yes | 1796 (61.5) | 1.54 (0.63, 3.92) | 640 | 65.2 | 586 | 62.8 | 449 | 59.9 | 121 | 47.5 | |
| No | 1119 (38.3) | 2.03 (0.80, 5.10) | 341 | 34.8 | 343 | 36.8 | 301 | 40.1 | 134 | 52.5 | |
| Unknown | 4 (0.13) | 1.75 (1.29, 2.37) | 0 | 0.0 | 4 | 0.4 | 0 | 0.0 | 0 | 0.0 | |
P-values were calculated using chi-square tests for categorical variables.